|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600121231 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-27 08:33:59 |
|
注册时间: Date of Registration: |
2026-03-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国高耐药屏障核苷(酸)类似物(NAs)治疗慢性乙型肝炎的多中心真实世界研究 |
|
Public title: |
Multicenter real-world study on high-resistance barrier nucleoside analogues for chronic hepatitis B in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国高耐药屏障核苷(酸)类似物(NAs)治疗慢性乙型肝炎的多中心真实世界研究(普众工程/CARE-BStudy) |
|
Scientific title: |
Multicenter real-world study on high-resistance barrier nucleoside analogues for chronic hepatitis B in China (Puzhong Engineering/Care-B Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈广 |
研究负责人: |
宁琴 |
|
Applicant: |
Chen Guang |
Study leader: |
Ning Qin |
|
申请注册联系人电话: Applicant telephone: |
+86 27 83663131 |
研究负责人电话: Study leader's telephone: |
+86 27 83662391 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
widechain@163.com |
研究负责人电子邮件: Study leader's E-mail: |
qning@vip.sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国湖北省武汉市硚口区解放大道1095号 |
研究负责人通讯地址: |
中国湖北省武汉市硚口区解放大道1095号 |
|
Applicant address: |
1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China |
Study leader's address: |
1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属同济医院 |
||
|
Applicant's institution: |
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属同济医院 |
||
|
Affiliation of the Leader: |
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
TJ-IRB202601057 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院附属同济医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-22 00:00:00 |
||
|
伦理委员会联系人: |
周璞 |
||
|
Contact Name of the ethic committee: |
Zhou Pu |
||
|
伦理委员会联系地址: |
中国湖北省武汉市硚口区解放大道1095号 |
||
|
Contact Address of the ethic committee: |
1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 83662379 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zhoupu_tjh@163.com |
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属同济医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国湖北省武汉市硚口区解放大道1095号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Independent subject(Self-financing) |
||||||||||||||||||||||
|
Target disease: |
Chronic hepatitis B |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1. 观察当前国内已上市高耐药屏障NAs治疗慢性乙型肝炎(CHB)的长期疗效与安全性特征; 2. 观察CHB患者肝细胞癌(HCC)发生率,尝试建立适合中国大陆CHB患者HCC预测的模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To characterize the long-term efficacy and safety profiles of currently available high genetic barrier nucleos(t)ide analogues (NAs) in the treatment of chronic hepatitis B (CHB) within the domestic population; 2. To evaluate the incidence of hepatocellular carcinoma (HCC) in CHB patients and endeavor to establish a predictive model tailored for HCC risk stratification in mainland Chinese CHB patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄为18~65周岁(含18周岁和65周岁),性别不限; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Aged 18 to 65 years (inclusive), irrespective of gender; |
||||||||||||||||||||||
|
排除标准: |
1.有证据提示为肝细胞癌(HCC)或血清甲胎蛋白(AFP)>100 μg/L,或肝硬化失代偿期; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Evidence suggestive of hepatocellular carcinoma (HCC), or serum alpha-fetoprotein (AFP) level > 100 μg/L, or decompensated cirrhosis; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-22 00:00:00至 To 2031-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-04-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据保存在电子数据捕获系统(EDC),申请者通过邮件联系主要研究者索取原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Raw data is stored in the Electronic Data Capture (EDC) system, and applicants may contact the principal investigator via email to request the raw data |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
研究数据的收集将采用统一的电子病例报告表(eCRF),由各中心的研究人员按照标准操作流程(SOP)录入电子数据捕获系统(EDC)。数据管理由牵头单位负责,定期进行数据核查和清理,确保数据的准确性和一致性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Study data will be collected using a unified electronic Case Report Form (eCRF). Researchers at each participating center will enter data into an Electronic Data Capture (EDC) system in accordance with Standard Operating Procedures (SOPs). The leading unit will be responsible for data management, conducting regular data verification and cleansing to ensure data accuracy and consistency. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |